A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination with Ipilimumab and Nivolumab in Patients with Unresectable Stage III or Stage IV Melanoma

Brief description of study

The main purpose of this study is to test the safety, tolerability, and effectiveness of the study drug tocilizumab when given with the drugs ipilimumab and nivolumab to patients with stage III or stage IV melanoma that cannot be removed by surgery.


Clinical Study Identifier: s19-00008
ClinicalTrials.gov Identifier: NCT03999749
Principal Investigator: Jeffrey S. Weber.


Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.